David Dillon David Dillon
    Senior Managing Scientist, Exponent International Ltd
  2. Registration

  3. Session 1: Overviews
  4. Member State overview

    • Experiences of BP/AS evaluations
    • Capacity
    • Workload, etc
    Maristella Rubbiani Maristella Rubbiani
    Head of Unit, Istituto Superiore di Sanità
  5. ECHA’s latest updates

    • Efficacy
    • Dissemination platform
    • In situ
    • Treated articles
    • BPFs, etc
    Erik van de Plassche Erik van de Plassche
    Chair Biocidal Products Committee Unit D1 – Biocides Assessment, European Chemicals Agency
  6. Update from the Commission: latest developments in the biocides field

    via video link

    Martinus Nagtzaam Martinus Nagtzaam
    Policy Officer, European Commission
  7. Q&A

  8. Refreshments

  9. The latest developments in antimicrobials field from the US

    Antimicrobials Division, Office of Pesticide Programs, U.S. Environmental Protection Agency, USA, tbc

  10. Q&A

  11. Session 2: Authorisation/ approval related issues
  12. Biocidal Product Family update

    • Changes to Nov. 2014 Notes for Guidance
    • Impact on already submitted BPFs
    • Consequences for BPF authorisations
  13. Experience with a Biocidal Product Family containing an unstable molecule. Consequences on:

    • Physical chemical tests
    • Efficacy
    • Storage stability
    • Human health risk assessment
    Daniela Romano Daniela Romano
    Regulatory Affair Manager for Biocidal Products, Eurofins Biolab
  14. Evaluation related issues

    • Transparency for evaluation of substances
    • Applicability of new guidance during evaluation
    • Tips for submitting additional data
  15. Industry Experience of Union Authorisation (PT2 and PT4)

    • Practical aspects of requirements
      • tight deadlines
      • availability of support
      • peer-review process
    • Managing National regulations at the same time
    Siobhan Murphy Siobhan Murphy
    Regulatory Specialist, Contec Cleanroom (UK) Ltd.
  16. Q&A

  17. Lunch

  18. Panel: How do Member States handle resourcing issues covering substances & products

    • Infringements of deadlines for evaluations
    • Advice to other MS/applicants


    Maristella Rubbiani, Head of Unit, Istituto Superiore di Sanità, Italy

    Birgitte Skou Cordua, AC-technician | Pesticides & Biocides, The Danish Environmental Protection Agency, Denmark

  19. Session 3: Risk Assessment
  20. The implementation of PT 21 assessment in Denmark

    Birgitte Skou Cordua Birgitte Skou Cordua
    Ecotoxicologist, Danish Environmental Protection Agency
  21. Overly conservative Risk Assessment

    • Treated article assessment
    • Silver  - a case study
    Andrew Goodyear Andrew Goodyear
    Partner, ERM
  22. Q&A

  23. Refreshments

  24. Session 4: Efficacy developments
  25. Overview of important efficacy developments

    David Ashworth David Ashworth
    Managing Director, Klarus Consulting Ltd, UK
  26. Latest updates for PT1-5

    Mike Baldry Mike Baldry
    Independent Consultant
  27. Latest updates for PT 11/12

  28. Q&A

  29. Close of Day One

View previous day / next day